80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC ≥1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC ≥50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC ≥50% stage II-IIIA NSCLC pts.